Dermapharm Holding SE Logo

Dermapharm Holding SE

Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.

DMP | F

Overview

Corporate Details

ISIN(s):
DE000A2GS5D8
LEI:
5299009F0KNZINQQQK37
Country:
Germany
Address:
Lil-Dagover-Ring 7, 82031 Grünwald
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dermapharm Holding SE is a manufacturer of patent-free branded pharmaceuticals and other healthcare products. Established in 1991, the company operates an integrated business model encompassing in-house research, development, production, and distribution. Its activities are primarily structured into two segments: "Branded pharmaceuticals and other healthcare products" and "Parallel import business." The company focuses on profitable, niche markets and implements a growth strategy that combines organic development with targeted acquisitions to expand its product portfolio and international footprint. Key assets include in-house R&D competence, a pipeline of development projects, and over 1,300 marketing authorizations for products such as over-the-counter medicines and herbal supplements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 07:30
Earnings Release
Dermapharm confirms stable business development in H1 2025 and records EBITDA g…
English 25.4 KB
2025-08-26 00:00
Interim Report
Half-yearly financial report 2025
English 1.5 MB
2025-08-18 09:26
Report Publication Announcement
English 4.0 KB
2025-08-12 07:30
Earnings Release
Dermapharm Holding SE remains on projected growth trajectory in Q2 2025
English 15.1 KB
2025-07-04 16:18
Director's Dealing
Dermapharm Holding SE: Wilhelm Beier, buy
English 5.8 KB
2025-07-01 12:30
Declaration of Voting Results & Voting Rights Announcements
German 12.3 KB
2025-06-27 14:40
Declaration of Voting Results & Voting Rights Announcements
English 12.0 KB
2025-06-26 17:43
Post-Annual General Meeting Information
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of…
English 10.9 KB
2025-06-24 16:46
Director's Dealing
Dermapharm Holding SE: Dr. Andreas Eberhorn, buy
English 5.8 KB
2025-06-05 12:29
Director's Dealing
Dermapharm Holding SE: Anja Schorn, buy
English 6.2 KB
2025-06-04 11:19
Director's Dealing
Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy
English 6.9 KB
2025-05-16 15:05
Pre-Annual General Meeting Information
Dermapharm Holding SE: Bekanntmachung der Einberufung zur Hauptversammlung am 2…
German 59.4 KB
2025-05-15 07:30
Earnings Release
Dermapharm Holding SE performs in line with projections in Q1 2025, confirms fu…
English 23.6 KB
2025-05-15 00:00
Interim Report
Q1 statement / Q1 financial report 2025
English 347.5 KB
2025-05-07 08:40
Report Publication Announcement
English 3.9 KB

Automate Your Workflow. Get a real-time feed of all Dermapharm Holding SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Dermapharm Holding SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-10-13 Kellinghusen, Dr. Georg Supervisory board Buy None 4,884.80 EUR
2021-07-22 Neumeyer, Hilde Board Buy None 163,938.30 EUR
2021-07-22 Wahl, Dr. Albert Board Buy None 8,514.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.